This week, MedTech Global Insights dives into the most significant U.S. regulatory shift of 2026: the FDA's new Quality Management System Regulation (QMSR). We uncover why this is far more than a simple alignment with international standards and exposes a new level of corporate liability.

The episode reveals how FDA inspectors now have unprecedented access to high-level management review meetings. We explore a real-world case where a company's internal decision to 'monitor' a component risk, once a private discussion, is now a transparent record for regulators, potentially creating massive legal and financial exposure after a single patient incident.

Key Takeaways:

- Why is the FDA's new QMSR more than just a paperwork update?

- What specific internal documents are now exposed to FDA inspectors for the first time?

- How does this rule change the personal liability of your executive team?

- Is your current "quality culture" strong enough to withstand direct regulatory scrutiny?

- What's the number one mistake companies are making in their management review meetings right now?

- How can you turn this new regulatory pressure into a competitive advantage?

Contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.